Join
Live feed
·
PRReleasevia Quantisnow
Eikon Therapeutics Inc. logo

Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer

ByQuantisnow·Wall Street's wire, on your screen.
EIKN· Eikon Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track EIKN (Eikon Therapeutics Inc.) and more on Quantisnow.